Gene · 4277
Papers3,381
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 3,381
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Structural Variation Detection and Association Analysis of Whole-Genome-Sequence Data from 16,905 Alzheimer's Diseases Sequencing Project Subjects. | Res Sq | 2023 | 37886469 | PubTator, text mining | PubMed |
| The transcriptome signature analysis of the epithelial-mesenchymal transition and immune cell infiltration in colon adenocarcinoma. | Sci Rep | 2023 | 37884639 | PubTator, text mining | PubMed |
| Immunological role and clinical prognostic significance of P2RY6 in lung adenocarcinoma: a multi-omics studies and single-cell sequencing analysis. | World J Surg Oncol | 2023 | 37880703 | PubTator, text mining | PubMed |
| Advances in immunotyping of colorectal cancer. | Front Immunol | 2023 | 37876934 | PubTator, text mining | PubMed |
| Advancements in CRISPR screens for the development of cancer immunotherapy strategies. | Mol Ther Oncolytics | 2023 | 37876793 | PubTator, text mining | PubMed |
| Differential gene expression of immunity and inflammation genes in colorectal cancer using targeted RNA sequencing. | Front Oncol | 2023 | 37869102 | PubTator, text mining | PubMed |
| Two bullets in the gun: combining immunotherapy with chemotherapy to defeat neuroblastoma by targeting adrenergic-mesenchymal plasticity. | Front Immunol | 2023 | 37849756 | PubTator, text mining | PubMed |
| Expression of CKS2 in Hepatocellular Carcinoma: Correlation with Survival Outcomes and Immune Microenvironment. | J Hepatocell Carcinoma | 2023 | 37841370 | PubTator, text mining | PubMed |
| Cytokines impact natural killer cell phenotype and functionality against glioblastoma in vitro. | Front Immunol | 2023 | 37841273 | PubTator, text mining | PubMed |
| Immunoediting of KEAP1-NRF2 mutant tumours is required to circumvent NRF2-mediated immune surveillance. | Redox Biol | 2023 | 37839356 | PubTator, text mining | PubMed |
| PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated? | Cancers (Basel) | 2023 | 37835376 | PubTator, text mining | PubMed |
| Complement receptor type 1 and 2 (CR1 and CR2) gene polymorphisms and plasma protein levels are associated with the Dengue disease severity. | Sci Rep | 2023 | 37833411 | PubTator, text mining | PubMed |
| Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management. | Int J Nanomedicine | 2023 | 37795042 | PubTator, text mining | PubMed |
| Copy number variations and their effect on the plasma proteome. | Genetics | 2023 | 37793096 | PubTator, text mining | PubMed |
| Lenalidomide improves NKG2D-based CAR-T cell activity against colorectal cancer cells invitro. | Heliyon | 2023 | 37790973 | PubTator, text mining | PubMed |
| Novel role of immune-related non-coding RNAs as potential biomarkers regulating tumour immunoresponse via MICA/NKG2D pathway. | Biomark Res | 2023 | 37784183 | PubTator, text mining | PubMed |
| Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies. | J Transl Med | 2023 | 37784157 | PubTator, text mining | PubMed |
| M6A methylation modification in autoimmune diseases, a promising treatment strategy based on epigenetics. | Arthritis Res Ther | 2023 | 37784134 | PubTator, text mining | PubMed |
| Tumorigenic effects of human mesenchymal stromal cells and fibroblasts on bladder cancer cells. | Front Oncol | 2023 | 37781195 | PubTator, text mining | PubMed |
| Comprehensive pan-cancer analysis reveals NUSAP1 is a novel predictive biomarker for prognosis and immunotherapy response. | Int J Biol Sci | 2023 | 37781040 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4277/papers?page=14